Lung Cancer News

National Comprehensive Cancer Network’s Oncology Research Program awarded three grants to support research into small cell lung cancer.

Adjuvant therapy with alectinib prolonged DFS compared with platinum-based chemotherapy for certain patients with lung cancer, according to the agent’s manufacturer.

Assessment of body composition measurements on lung screening low-dose CT scans revealed patients at high risk for mortality due to lung cancer, cardiovascular disease and all causes, according to results published in Radiology.

Stereotactic ablative radiotherapy with immunotherapy significantly improvement EFS among patients with early-stage, treatment-naive or lung parenchymal recurrent node-negative non-small cell lung cancer, according to study results.

In the ONCO-DVT trial, patients with cancer and isolated distal deep vein thrombosis had fewer thrombotic events at 1 year with 12-month vs. 3-month edoxaban therapy, a finding that could change clinical guidance, according to a speaker.

Researchers have developed a method to predict which individuals are at higher risk for lung cancer-related mortality.

Combining weight-based dosing and single-use vial sharing within individual Veterans Affairs hospitals could reduce immune checkpoint inhibitor spending by millions annually, according to study results published in Health Affairs.

Divarasib induced durable clinical responses among patients with KRAS G12C-positive solid tumors, according to study findings published in The New England Journal of Medicine.

Selpercatinib extended PFS compared with a PD-1 inhibitor-chemotherapy combination for certain adults with advanced non-small cell lung cancer, according to topline data released by the agent’s manufacturer.

After decades of developmental challenges, antibody-drug conjugates have emerged as potentially less toxic and more effective treatment options for a variety of malignancies.